Guardant Health Offers Free CRC Screening Tests to Community Groups
Event summary
- Guardant Health launched a grant program offering up to 100 free Shield CRC blood tests to community organizations for March screening events.
- Applications for the program are due February 17, 2026, with approvals announced February 20, 2026.
- Shield is the only FDA-approved blood test for primary CRC screening in average-risk adults aged 45+.
- The program aims to increase screening participation in underserved communities during CRC Awareness Month.
The big picture
Guardant Health's grant program reflects growing industry focus on accessible cancer screening solutions. The initiative aligns with broader trends toward preventive care and health equity, particularly as colorectal cancer remains the second leading cause of cancer deaths in the U.S. The program could position Guardant as a leader in community-focused oncology solutions, though its long-term impact will depend on participation rates and screening outcomes.
What we're watching
- Adoption Pace
- How quickly community organizations will leverage this program to expand CRC screening access.
- Market Positioning
- Whether this initiative will strengthen Guardant's competitive position in the CRC screening market.
- Regulatory Impact
- The extent to which FDA approval of Shield will influence broader adoption of blood-based cancer screening.
Related topics